What a treatment is, who regulates it, and what to ask. 222 articles, newest first.
BOTOX Cosmetic's lateral-canthal approval concerns lines associated with muscle activity, and its pivotal response assessment was made at maximum smile. That is a narrower result than a promise to erase lines visible at rest.
A peel marketed for “acne” may be aimed at clogged pores, lingering color, or a structural scar. Those are not interchangeable endpoints, and current acne guidelines do not make a routine procedural recommendation for peels because the evidence is insufficient.
Midlife weight change and hormone treatment often happen together, but timing is not proof of cause. Trials and Menopause Society guidance support a narrower answer than either 'HRT makes you gain' or 'HRT is a weight-loss treatment.'
Both can deliver systemic estradiol, but a patch bypasses first-pass liver exposure and has a different practical schedule. Route-related clot-risk evidence, uterine protection, product labeling and adherence all matter; neither route is automatically safe or suitable for everyone.
The current international PMOS guideline allows consideration of certain anti-obesity medicines for higher weight under general-population criteria. It does not turn a GLP-1 prescription into an FDA-approved PMOS treatment or a proven route to pregnancy.
Removing the uterus is not the same as removing the ovaries. The surgical record, reason for surgery, symptoms, age, and any endometriosis history help determine what a menopause-hormone-therapy conversation should cover.
Cosmetic Botox does not switch on or off at a single date. The first visible change, a study-defined response, and the gradual return of movement are different checkpoints; the right follow-up compares the same muscle, product, goal, and baseline.
A HydraFacial can include a mild peel step, so this is not a choice between acid and no acid. Compare the full branded facial protocol with a separately specified peel by goal, depth, ingredients, recovery and the outcome the practice can actually support.
Neither filler family is universally better. The useful comparison names two specific products, the proposed treatment area, each FDA-approved indication, the relevant cautions, and the clinician's plan.
Treated hairs can remain visible, seem to grow, and shed over days to weeks after a laser session. That appearance alone cannot prove success or failure; later regrowth and a skin reaction are separate questions.
A low testosterone result is not a scalp-hair diagnosis, and alopecia reports in testosterone-product labeling do not prove every change during TRT was caused by the drug. Pattern, timeline, and competing causes matter.
Small studies of scalp microneedling, often combined with another hair-loss treatment, are not the same as FDA clearance for hair regrowth. Use the diagnosis, regimen and device status to evaluate an offer.
Two ingredients appear under four familiar brands, but approvals belong to exact products and populations. This October 2026 label map separates diabetes, chronic weight management, cardiovascular, kidney, sleep-apnea, and MASH claims without ranking effectiveness.
Menopausal hormone therapy can address symptoms but should not be assumed to prevent pregnancy. During perimenopause, a clinician may need to solve symptom control, contraception, bleeding assessment, and product safety as separate parts of one plan.
POI before 40 changes the goals and time horizon of a hormone-therapy conversation. It also calls for diagnostic, bone-health, fertility, and follow-up questions that a routine menopause visit may not answer.
Local vaginal estrogen is a guideline-supported prevention discussion for some people in perimenopause or after menopause with recurrent UTIs. It is not treatment for an active infection, and a U.S. product's vaginal-atrophy indication is not an FDA approval specifically for UTI prevention.
Stopping TRT is a clinical review, not a universal taper recipe. A prescriber should revisit the original diagnosis, benefit, product, fertility plans, symptoms, and a follow-up plan before making a change.
These oral weight-management medicines combine different drugs and require different screening. Opioid exposure, seizure history, pregnancy potential, eye conditions and follow-up can change the decision before efficacy is compared.
A facial, medical comedone extraction, injection and incision-and-drainage are different services. Identify the lesion and the operator's authority, then separate removal of existing material from prevention of new acne.
G-prime describes a gel's elastic response under specified laboratory conditions. It is one material property, not a universal measure of lift, longevity, safety, or the right filler for a particular face.
Pancreatitis and gallbladder disease are separate labeled concerns. Abdominal symptoms cannot reliably distinguish them at home, and severe or persistent pain should not be dismissed as a routine treatment effect.
Wegovy and Zepbound labeling distinguishes rodent C-cell tumors, uncertain human relevance, and specific MTC or MEN2 contraindications. A vague history of thyroid disease is not enough to interpret that warning.
An injectable magnesium product can have specific medical uses without validating a wellness add-on. Identify the salt, the clinical reason for intravenous delivery, kidney assessment and monitoring plan.
Hair-targeting lasers can have a role in diagnosed hidradenitis suppurativa. Device-specific studies assess inflammatory disease response, which is different from cosmetic hair reduction or removal of established tunnels.
Two products placed in the vagina can have different treatment targets and systemic exposure. Estring and Femring illustrate why a ring's location alone does not establish a low-dose local therapy.
A device cleared for acne scars is not thereby cleared to treat ongoing breakouts. A consultation should identify the current lesions, the actual treatment target, and whether the scar appointment should wait.
PMMA filler contains nonabsorbable particles, so choosing it is a lasting material decision rather than simply buying a longer interval between visits. FDA's 2026 Bellafill-to-SANAE trade-name change does not by itself establish a new indication.
Feeling better or measuring hormone absorption does not establish that a progesterone cream adequately protects the uterine lining during systemic estrogen therapy. The evidence must match the exact product, route, and regimen.
Semaglutide can be considered for selected adults after bariatric surgery. The decision starts with the operation, weight trajectory, nutrition and symptoms—not an assumption that adding medication means the operation failed.
Optic-nerve injury and diabetic retinal disease are different concerns with different evidence. Current European NAION labeling should be identified as European, while U.S. product labeling and the patient's eye history remain separate records.
Fezolinetant and elinzanetant are nonhormonal prescription options for moderate to severe menopausal vasomotor symptoms. They do not replace every role of hormone therapy, and their liver, interaction, and other precautions are not identical.
Visible gum during a smile can reflect lip movement, gum and tooth relationships, jaw structure, or a combination. An off-label neuromodulator changes muscle activity, not every cause of gingival display.
A result fading in photographs does not prove all filler has disappeared. Separate clinical correction, a study's follow-up period, and imaging-detectable material before discussing another injection.
Hair reduction can be part of care for pseudofolliculitis barbae, but a recurring bump is not automatically an ingrown hair. Confirm the problem and distinguish fewer inflammatory bumps from a cosmetic hair-removal endpoint.
Laser can address unwanted hair without treating PCOS itself. A useful plan separates the hair-reduction course, possible future growth, endocrine care, and the point at which the approach is reassessed.
Microbotox and mesobotox are not standardized product names. Clarify whether the proposal is intradermal injection, intramuscular injection, or topical toxin after microneedling before interpreting its evidence or regulatory status.
Addyi and Vyleesi are FDA-approved products for different labeled populations with acquired, generalized HSDD, routes, and schedules. No testosterone product is FDA approved in the United States for female sexual dysfunction, so off-label and compounded testosterone follow different product and evidence pathways.
An off-the-shelf adipose allograft comes from donor tissue, an autologous fat graft is harvested from the same patient during surgery, and dermal filler is a manufactured implant with product-specific FDA approvals. They do not share one regulatory path, evidence base, reversibility profile, or treatment record.
Alarplasty changes the nostril base through limited sill or alar excisions; rhinoplasty can change the broader nasal framework. A small incision does not make the decision small: base width, flare, symmetry, scars, tip support, and breathing still need one plan.
An at-home red/blue LED acne device and a prescription 1726-nm clinic laser use different wavelengths, targets, controls, treatment schedules, claims, evidence, and operators. FDA clearance belongs to an exact model and indication; it does not make every acne light equivalent or establish a universal winner.
A beard or mustache transplant moves follicles; it does not create a separate facial-hair type. The plan should protect the donor supply and match caliber, curl, color, growth behavior, border softness, direction, density priorities, grooming, scarring, and future hair-loss needs.
A breast-reduction skin pattern controls the external envelope and scar; a pedicle preserves a tissue connection to the nipple-areola complex; a free nipple graft detaches and grafts that complex. These choices are related but not interchangeable, and no single size cutoff determines the plan for everyone.
A cheek implant adds a shaped solid device at the skeleton, filler adds a manufactured injectable at selected planes, and fat grafting transfers living tissue from a donor site. The right comparison starts with the missing three-dimensional structure, not the word “volume.”
Dermaplaning uses a blade to remove surface scale and vellus hair; microdermabrasion uses controlled abrasion, often with suction; a superficial chemical peel uses a defined agent to create a controlled chemical injury. The evidence, depth, recovery, sanitation, and skin-fit questions are different.
Hand filler and fat grafting address dorsal volume loss through different product and procedure pathways. Lasers, light devices, and peels target surface findings such as pigment or texture instead. A useful plan identifies the primary deficit before combining treatments.
Laser hair removal aims for stable long-term reduction through repeated light-based treatment of suitable pigment targets. Waxing and sugaring pull visible hair from the root for a temporary result. Compare hair color and cycle, skin response, interval, irritation, maintenance, provider, and total course.
“MIC,” “lipotropic,” and “skinny shot” are not standardized finished products. Methionine, inositol, choline, B12, carnitine, and other ingredients can vary by clinic and pharmacy; evidence for one oral nutrient or deficiency treatment does not prove that an injected mixture causes weight loss.
Ear pinning is not one maneuver. A complete otoplasty plan identifies the antihelical fold, conchal depth, ear-to-head angle, lobe, asymmetry, cartilage strength, incisions, sutures, and whether cartilage is bent, scored, removed, or combined.
